Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
17 May 2024 - 6:05AM
Roivant (Nasdaq: ROIV) today announced that it will host a live
conference call and webcast at 8:00 a.m. ET on Thursday, May 30,
2024, to report its financial results for the fourth quarter and
fiscal year ended March 31, 2024, and provide a business update.
To access the conference call by phone, please register online
using this registration link. The presentation and webcast
details will also be available under “Events & Presentations”
in the Investors section of the Roivant website at
https://investor.roivant.com/news-events/events. The archived
webcast will be available on Roivant’s website after the conference
call.
About Roivant
Roivant is a commercial-stage biopharmaceutical company that
aims to improve the lives of patients by accelerating the
development and commercialization of medicines that matter. Today,
Roivant’s pipeline includes VTAMA, a novel topical approved for the
treatment of psoriasis and in development for the treatment of
atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal
antibodies targeting the neonatal Fc receptor (“FcRn”) in
development across several IgG-mediated autoimmune indications; and
brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1
for the treatment of dermatomyositis and non-infectious uveitis, in
addition to other clinical stage molecules. We advance our pipeline
by creating nimble subsidiaries or “Vants” to develop and
commercialize our medicines and technologies. Beyond therapeutics,
Roivant also incubates discovery-stage companies and health
technology startups complementary to its biopharmaceutical
business. For more information, www.roivant.com.
Roivant Forward-Looking Statements
This press release contains forward-looking statements.
Statements in this press release may include statements that are
not historical facts and are considered forward-looking within the
meaning of Section 27A of the Securities Act of 1933, as amended
(the “Securities Act”), and Section 21E of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), which are usually
identified by the use of words such as “anticipate,” “believe,”
“continue,” “could,” “estimate,” “expect,” “intends,” “may,”
“might,” “plan,” “possible,” “potential,” “predict,” “project,”
“should,” “would” and variations of such words or similar
expressions. The words may identify forward-looking statements, but
the absence of these words does not mean that a statement is not
forward-looking. We intend these forward-looking statements to be
covered by the safe harbor provisions for forward-looking
statements contained in Section 27A of the Securities Act and
Section 21E of the Exchange Act.
Our forward-looking statements include, but are not limited to,
statements regarding our or our management team’s expectations,
hopes, beliefs, intentions or strategies regarding the future, and
statements that are not historical facts, including statements
about potential share repurchases, the clinical and therapeutic
potential of our products and product candidates, the availability
and success of topline results from our ongoing clinical trials and
any commercial potential of our products and product candidates. In
addition, any statements that refer to projections, forecasts or
other characterizations of future events or circumstances,
including any underlying assumptions, are forward-looking
statements.
Although we believe that our plans, intentions, expectations and
strategies as reflected in or suggested by those forward-looking
statements are reasonable, we can give no assurance that the plans,
intentions, expectations or strategies will be attained or
achieved. Furthermore, actual results may differ materially from
those described in the forward-looking statements and will be
affected by a number of risks, uncertainties and assumptions,
including, but not limited to, those risks set forth in the Risk
Factors section of our filings with the U.S. Securities and
Exchange Commission. Moreover, we operate in a very competitive and
rapidly changing environment in which new risks emerge from time to
time. These forward-looking statements are based upon the current
expectations and beliefs of our management as of the date of this
press release and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those
described in the forward-looking statements. Except as required by
applicable law, we assume no obligation to update publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:
InvestorsRoivant Investor Relationsir@roivant.com
MediaStephanie LeeRoivant Sciencesstephanie.lee@roivant.com
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Nov 2024 to Dec 2024
Roivant Sciences (NASDAQ:ROIV)
Historical Stock Chart
From Dec 2023 to Dec 2024